Report: Diverse asthma pipeline presents major opportunity for investors
The active and diverse treatment pipeline for asthma boasts a striking level of innovation, with many first-in-class products representing significant investment opportunities, according to business intelligence provider GBI Research.
The company’s latest report found that that while asthma therapy development is dominated by small molecule compounds, with 156 products representing 67% of the pipeline, the R&D landscape has moved towards biologics on an unprecedented scale. There are now 60 biologics in the pipeline, representing a 26% share. Yasser Mushtaq, senior analyst for GBI Research, said: “There is a high degree of innovation across the entire asthma therapeutics pipeline. This includes Phase III, consisting of multiple first-in-class drugs, many of which are biologics.”
Opportunity for investors
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze